---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-089773"
form_type: "8-K"
ticker: "BTAI"
cik: "0001720893"
company_name: "BioXcel Therapeutics, Inc."
filed_at: "2025-09-15T23:59:59+00:00"
generated_at: "2026-05-17T06:38:54.886645+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# BioXcel completes enrollment for mCGI-S/PEC study; sNDA submission expected Q1 2026

## Summary
- Open-label study of ~30 patients evaluating mCGI-S vs PEC scale enrolled on Sept 13, 2025; results due Q4 2025.
- sNDA for BXCL501 SERENITY At-Home program planned for Q1 2026, incorporating this and prior Phase 3 safety data.
- Raised $37.3M from July 1 to Sept 15, 2025 via ATM ($27.6M) and warrant exercises ($9.7M).
- As of Sept 12, 2025, shares outstanding totaled 19,646,801; cash expected to fund operations into Q1 2026.

## SEC filing metadata
- accession: 0001104659-25-089773
- form_type: 8-K
- ticker: BTAI
- cik: 0001720893
- company_name: BioXcel Therapeutics, Inc.
- filed_at: 2025-09-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720893/000110465925089773/0001104659-25-089773-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720893/000110465925089773/tm2526080d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-089773
- JSON: https://secwatch.observer/filing/0001104659-25-089773.json
- Plain text: https://secwatch.observer/filing/0001104659-25-089773.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.